LUPIN - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.3
| Stock Code | LUPIN | Market Cap | 1,07,324 Cr. | Current Price | 2,348 ₹ | High / Low | 2,494 ₹ |
| Stock P/E | 17.8 | Book Value | 659 ₹ | Dividend Yield | 0.51 % | ROCE | 26.6 % |
| ROE | 22.2 % | Face Value | 2.00 ₹ | DMA 50 | 2,285 ₹ | DMA 200 | 2,187 ₹ |
| Chg in FII Hold | 0.20 % | Chg in DII Hold | -0.26 % | PAT Qtr | 1,797 Cr. | PAT Prev Qtr | 1,241 Cr. |
| RSI | 62.6 | MACD | 5.01 | Volume | 12,69,168 | Avg Vol 1Wk | 8,48,727 |
| Low price | 1,837 ₹ | High price | 2,494 ₹ | PEG Ratio | 0.12 | Debt to equity | 0.04 |
| 52w Index | 77.7 % | Qtr Profit Var | 39.2 % | EPS | 139 ₹ | Industry PE | 32.5 |
📊 Analysis: Lupin (LUPIN) demonstrates strong fundamentals with ROE at 22.2% and ROCE at 26.6%, indicating efficient capital utilization. Valuation is attractive with a P/E of 17.8 compared to the industry average of 32.5, suggesting undervaluation. The [PEG ratio](ca://s?q=Explain_PEG_ratio) of 0.12 highlights excellent alignment between price and growth. Dividend yield of 0.51% provides modest income support. Technicals show the stock trading near its highs with RSI at 62.6, suggesting neutral-to-positive momentum. Quarterly PAT surged (1,797 Cr vs 1,241 Cr), reflecting strong earnings growth.
💡 Entry Price Zone: Ideal accumulation range is 2,200–2,300 ₹, aligning with [DMA 50](ca://s?q=Explain_DMA_in_stocks) (2,285 ₹) and [DMA 200](ca://s?q=Explain_DMA_in_stocks) (2,187 ₹). Current price (2,348 ₹) is slightly above this zone but remains attractive for long-term investors.
📈 Exit / Holding Strategy: If already holding, maintain a long-term horizon (5+ years) given strong profitability and undervaluation. Exit partially near 2,450–2,500 ₹ resistance if valuations stretch, but long-term compounding potential remains strong with high ROE, ROCE, and earnings growth.
✅ Positive
- 📌 Strong [ROE](ca://s?q=Explain_ROE) (22.2%) and [ROCE](ca://s?q=Explain_ROCE) (26.6%).
- 📌 Attractive [P/E ratio](ca://s?q=What_is_PE_ratio) (17.8 vs industry 32.5).
- 📌 EPS at 139 ₹ reflects robust profitability.
- 📌 FII holdings increased (+0.20%), showing foreign investor confidence.
⚠️ Limitation
- 📌 Dividend yield is modest (0.51%), limiting income potential.
- 📌 DII holdings decreased (-0.26%), showing reduced domestic institutional support.
📉 Company Negative News
- 📌 DII holdings decline (-0.26%) indicates weaker domestic institutional sentiment.
📈 Company Positive News
- 📌 Quarterly PAT surged (1,797 Cr vs 1,241 Cr), showing strong earnings momentum.
- 📌 EPS growth supports valuation strength.
🏭 Industry
- 📌 Pharma sector average P/E is 32.5, higher than Lupin’s valuation.
- 📌 Industry growth remains steady, driven by global demand for generics and specialty drugs.
🔎 Conclusion
Lupin is fundamentally strong and undervalued relative to industry peers, making it a good candidate for long-term investment. Ideal entry is 2,200–2,300 ₹, but current levels remain attractive for accumulation. Existing holders should maintain a 5+ year horizon, with partial profit booking near 2,450–2,500 ₹ if valuations stretch. Strong ROE, ROCE, and earnings growth support long-term compounding potential.